Fulcrum Therapeutics (NASDAQ:FULC) Stock Bumped Up to “Hold” by Wall Street Zen

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $8.20.

Check Out Our Latest Stock Report on FULC

Fulcrum Therapeutics Trading Up 2.4%

Shares of NASDAQ:FULC opened at $3.77 on Friday. The stock has a market capitalization of $287.95 million, a PE ratio of -3.62 and a beta of 2.82. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74. The firm has a fifty day moving average price of $3.73 and a 200 day moving average price of $5.55.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). On average, sell-side analysts forecast that Fulcrum Therapeutics will post -0.60 earnings per share for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in shares of Fulcrum Therapeutics by 39.4% during the 3rd quarter. Marshall Wace LLP now owns 1,893,289 shares of the company’s stock worth $7,005,000 after buying an additional 534,866 shares during the period. Empowered Funds LLC bought a new position in Fulcrum Therapeutics in the 3rd quarter worth $329,000. Nantahala Capital Management LLC raised its holdings in Fulcrum Therapeutics by 20.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 6,575,352 shares of the company’s stock worth $24,329,000 after acquiring an additional 1,100,312 shares during the period. Alps Advisors Inc. raised its holdings in Fulcrum Therapeutics by 48.4% in the 3rd quarter. Alps Advisors Inc. now owns 100,366 shares of the company’s stock worth $371,000 after acquiring an additional 32,734 shares during the period. Finally, ProShare Advisors LLC acquired a new position in Fulcrum Therapeutics during the 3rd quarter worth $41,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

(Get Free Report)

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.

Read More

Analyst Recommendations for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.